Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Non-small Cell Lung Cancer

Trial Profile

Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs PD 325901 (Primary) ; Capecitabine; Dacomitinib; Docetaxel; Irinotecan
  • Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms M13DAP
  • Most Recent Events

    • 08 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 10 Nov 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 23 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top